| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df35025921b2d5044db377ee4697e53d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-17002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1793
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1875 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 |
| filingDate |
2020-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff39748f2156b26e9a2ef79a1f6dc9c8 |
| publicationDate |
2021-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3922258-A1 |
| titleOfInvention |
Therapeutic composition for use in the treatment of covid-19 and other cytokine storm associated disorders |
| abstract |
It is disclosed a therapeutic composition for use in the treatment of COVID-19 and other cytokine storm associated disorders, wherein the therapeutic composition comprises at least one active agent being selected from the following active agent groups a) to e):a) complement factor 3-targeting inhibitor of complement activation cascadeb) carboxypeptidase B enzymec) complement factor 5a receptor-targeting inhibitor of complement activation cascaded) endothelin A receptor-targeting inhibitor of extravasatione) bone morphogenic protein.It is further diclosed a method of treating COVID-19 and other cytokine storm associated disorders, wherein said method comprises administering an effective amount of at least one active agent being selected from the above mentioned active agent groups a) to e). |
| priorityDate |
2020-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |